Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12605000650695
Ethics application status
Approved
Date submitted
10/09/2005
Date registered
17/10/2005
Date last updated
6/11/2012
Type of registration
Prospectively registered
Titles & IDs
Public title
A study to determine if IL-4 is useful as a marker of inflammation of atherosclerosis
Query!
Scientific title
A study to determine if IL-4 is useful as a marker of inflammation of atherosclerosis
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Atherosclerosis in ischaemic heart disease.
783
0
Query!
Condition category
Condition code
Cardiovascular
857
857
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
This pilot study involves the testing of a new assay to detect IL-4. A once only sample of two mls of blood will be taken from 4 specific groups of patients to test for the presence of IL-4. The cytokine, IL-4, measured by this new assay, is abnormally elevated in the blood of patients with coronary artery disease, the degree of abnormality of blood IL-4 is related to important clinical events in such patients, including severity of disease, acute complications and treatment.
Query!
Intervention code [1]
449
0
Early detection / Screening
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
1100
0
To measure IL-4 by a new rapid point-of-care technique in patients with documented coronary artery disease presenting in a variety of acute clinical circumstances
Query!
Assessment method [1]
1100
0
Query!
Timepoint [1]
1100
0
Query!
Secondary outcome [1]
2036
0
To evaluate any abnormal measurements in relation to the severity of the disease, acute vascular complications and newly prescribed medication.
Query!
Assessment method [1]
2036
0
Query!
Timepoint [1]
2036
0
Query!
Eligibility
Key inclusion criteria
All patients presenting in the settings described will be eligible to participate. There will be no criteria for exclusion, apart from unwillingness to participate. It is proposed initially to study four small groups of patients with ischaemic heart disease. 1. Patients with unstable coronary artery disease admitted for Coronary Care will be studied on admission and then daily until coronary angiography is performed (or decided against). The IL-4 results will be related to the patient's clinical course, ECG changes, cardiac enzyme levels and angiographic findings. 2. Patients having coronary angioplasty, who have not been studied as part of group 1, will be studied before, immediately after and 24 hours after the procedure. The IL-4 results will be used to assess whether it can relate to the iatrogenic plaque rupture which this procedure involves. 3. Patients having coronary artery bypass grafting will be studied before, immediately after and 24 hours after surgery. On pump and off pump procedures (half in each subgroup) will be separately studied. The IL-4 results will be related to the extent (number of grafts) and duration of the surgical procedure. 4. Patients with stable coronary artery disease about to receive statin and/or angiotensin-converting enzyme inhibitor therapy will be studied before and twice weekly after the commencement of therapy for four weeks. The IL-4 results will be related to the dose and duration of drug therapy.
Query!
Minimum age
No limit
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Unwillingness to participate.
Query!
Study design
Purpose
Screening
Query!
Duration
Cross-sectional
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/01/2006
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
80
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
943
0
Hospital
Query!
Name [1]
943
0
Intensive Care Departmental Funding, Royal Melbourne Hospital
Query!
Address [1]
943
0
Query!
Country [1]
943
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Intensive Care Unit, RMH
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
803
0
None
Query!
Name [1]
803
0
Nil
Query!
Address [1]
803
0
Query!
Country [1]
803
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
2241
0
Royal Melbourne Hospital
Query!
Ethics committee address [1]
2241
0
Query!
Ethics committee country [1]
2241
0
Australia
Query!
Date submitted for ethics approval [1]
2241
0
Query!
Approval date [1]
2241
0
Query!
Ethics approval number [1]
2241
0
Query!
Summary
Brief summary
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
36103
0
Query!
Address
36103
0
Query!
Country
36103
0
Query!
Phone
36103
0
Query!
Fax
36103
0
Query!
Email
36103
0
Query!
Contact person for public queries
Name
9638
0
Dr Julian Hunt-Smith
Query!
Address
9638
0
Intensive Care Unit
Royal Melbourne Hospital
Grattan Street
Parkville VIC 3050
Query!
Country
9638
0
Australia
Query!
Phone
9638
0
+61 3 93427441
Query!
Fax
9638
0
+61 3 93428812
Query!
Email
9638
0
[email protected]
Query!
Contact person for scientific queries
Name
566
0
Dr Julian Hunt-Smith
Query!
Address
566
0
Intensive Care Unit
Royal Melbourne Hospital
Grattan Street
Parkville VIC 3050
Query!
Country
566
0
Australia
Query!
Phone
566
0
+61 3 93427710
Query!
Fax
566
0
+61 3 93428812
Query!
Email
566
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF